Your browser doesn't support javascript.
loading
Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas.
Hu, Xiaojie; Li, Wenbin; Zeng, Kang; Xu, Zhongyuan; Li, Changxing; Kang, Zhuang; Li, Shenglan; Huang, Xin; Han, Pu; Lin, Hongmei; Hui, Ai-Min; Tan, Yan; Diao, Lei; Li, Ben; Wang, Xingli; Wu, Zhuli; Lin, Xiaoxi.
Afiliação
  • Hu X; Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, China.
  • Li W; Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, 119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, China.
  • Zeng K; Department of Dermatology, NanFang Hospital Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, Guangdong, 510515, China.
  • Xu Z; Clinical Pharmacy Center, Nanfang Hospital Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, Guangdong, 510515, China.
  • Li C; Department of Dermatology, NanFang Hospital Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, Guangdong, 510515, China.
  • Kang Z; Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, 119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, China.
  • Li S; Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, 119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, China.
  • Huang X; Beijing Fosun Pharmaceutical Research and Development Co., Ltd, 1289 Yishan Road, Shanghai, 200233, China.
  • Han P; Beijing Fosun Pharmaceutical Research and Development Co., Ltd, 1289 Yishan Road, Shanghai, 200233, China.
  • Lin H; Beijing Fosun Pharmaceutical Research and Development Co., Ltd, 1289 Yishan Road, Shanghai, 200233, China.
  • Hui AM; Fosun Pharma USA Inc., 91 Hartwell Ave Suite 305, Lexington, MA, 02421, USA.
  • Tan Y; EnCureGen Pharma, 9 Yayingshi Road, Guangzhou, 510525, China.
  • Diao L; Beijing Fosun Pharmaceutical Research and Development Co., Ltd, 1289 Yishan Road, Shanghai, 200233, China.
  • Li B; Beijing Fosun Pharmaceutical Research and Development Co., Ltd, 1289 Yishan Road, Shanghai, 200233, China.
  • Wang X; Beijing Fosun Pharmaceutical Research and Development Co., Ltd, 1289 Yishan Road, Shanghai, 200233, China.
  • Wu Z; Shanghai Fosun Pharmaceutical Development Co., Ltd, 1289 Yishan Road, Shanghai, 20033, China.
  • Lin X; Shanghai Fosun Pharmaceutical Development Co., Ltd, 1289 Yishan Road, Shanghai, 20033, China. wuzhuli@fosunpharma.com.
BMC Med ; 21(1): 230, 2023 07 03.
Article em En | MEDLINE | ID: mdl-37400844
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neurofibromatose 1 / Neurofibroma Plexiforme Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Revista: BMC Med Assunto da revista: MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neurofibromatose 1 / Neurofibroma Plexiforme Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Revista: BMC Med Assunto da revista: MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China